AMPLY was founded by Dr. Ben Thomas, Dermot Tierney, and Prof. Chris Creevey, as a spin-out from Queen's University Belfast, building on over a decade of research.

AMPLY's platform combines AI, Next Generation Sequencing, and Synthetic Biology to target diseases linked to genetic variations and improve treatment efficacy.

A spokesperson for AMPLY emphasized that existing treatments often fail due to a lack of personalized approaches, which affects cancer survival rates and contributes to antimicrobial resistance.

AMPLYfolioAI, the company's proprietary tool, is designed to decode complex diseases, create smarter biologic drugs, and streamline the drug development process.

AMPLY is focusing on antimicrobial resistance, which is responsible for over 1.27 million deaths globally each year, and is developing new antimicrobials quickly and cost-effectively.

Belfast-based AMPLY Discovery has secured $1.75 million in seed funding to enhance its AI-driven drug discovery platform.

The funding round was led by Twin Path Ventures, with contributions from Venture Science, Co-fund NI, the British Business Bank, and QUBIS Limited.

The company is also working on preclinical drug discovery programs for nebulized treatments targeting chronic and drug-resistant lung infections.

In addition to antimicrobial resistance, AMPLY is developing innovative gene-silencing therapies for aggressive cancers, including triple-negative breast cancer and acute myeloid leukaemia.

Mr. Tierney described the funding success as a strong endorsement of AMPLY's work, particularly in a challenging fundraising environment for early-stage biotech companies.

Dr. Ben Thomas, CEO of AMPLY, is personally motivated to address the shortcomings of current treatments due to his father's death from a drug-resistant infection.

The platform allows for multiple drug discovery programs, validating its technology against diseases with limited existing treatments.